Quarterly report pursuant to Section 13 or 15(d)

Description of Business and Basis of Presentation - Additional Information (Detail)

v3.24.2.u1
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Basis Of Presentation [Line Items]          
Net Income (Loss) $ (2,798) $ (4,868) $ (9,283) $ (10,717)  
Proceeds from the sale of common stock and pre-funded warrants, net of fees     2,786 8,502  
Working capital 9,100   9,100   $ 5,200
Cash and cash equivalents 5,272   5,272   6,566
Accounts receivable, net $ 4,842   $ 4,842   $ 5,483
Common Stock, Par or Stated Value Per Share $ 0.001   $ 0.001   $ 0.001
Principal Payment On Loan     $ 865 0  
Proceeds from disposal of property, plant, and equipment     284 $ 0  
February 2024 Public Offering [Member]          
Basis Of Presentation [Line Items]          
Net Income (Loss)     (9,300)    
Proceeds from the sale of common stock and pre-funded warrants, net of fees     5,800    
Principal Payment On Loan     900    
Proceeds from disposal of property, plant, and equipment     $ 300    
2024 Annual Meeting [Member]          
Basis Of Presentation [Line Items]          
Common Stock, Par or Stated Value Per Share 0.001   $ 0.001    
Reverse Stock Split     a reverse stock split of BIOLASE common stock, par value $0.001 per share (the “common stock”), at a ratio between one-for-two (1:2) and one-for-fifty (1:50) with the ratio to be determined at the discretion of the Board    
Biolase Stockholders [Member]          
Basis Of Presentation [Line Items]          
Common Stock, Par or Stated Value Per Share $ 0.001   $ 0.001    
Reverse Stock Split     a reverse stock split of BIOLASE common stock, par value $0.001 per share (the “common stock”), at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors (the "Board") approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of the common stock (the “2023 Reverse Stock Split”).